Pages that link to "Q28486435"

The following pages link to Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells (Q28486435):

Displaying 24 items.

• Systematic Quality Control Analysis of LINCS Data (Q28818488) (← links)
• Microenvironmental regulation of therapeutic response in cancer (Q33654609) (← links)
• Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic (Q34817365) (← links)
• A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. (Q35263202) (← links)
• NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. (Q35851832) (← links)
• The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways (Q35856790) (← links)
• Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer (Q36066539) (← links)
• Modeling selective elimination of quiescent cancer cells from bone marrow (Q36360112) (← links)
• Targeted drug discovery for pediatric leukemia (Q36989223) (← links)
• The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond (Q38216649) (← links)
• Targeting PI3K/AKT/mTOR network for treatment of leukemia. (Q38364871) (← links)
• Novel approaches to pediatric leukemia treatment (Q38500371) (← links)
• Novel drug therapies in myeloid leukemia (Q38510486) (← links)
• FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions (Q38675400) (← links)
• FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia (Q38892684) (← links)
• The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia (Q39297348) (← links)
• Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis (Q42376734) (← links)
• A Facile, In Vitro 384-Well Plate System to Model Disseminated Tumor Cells in the Bone Marrow Microenvironment (Q47445458) (← links)
• Persistent DNA strand breaks induce a CAF-like phenotype in normal fibroblasts. (Q55078362) (← links)
• Therapeutic Vulnerabilities in -Mutant AML Unmasked by Palbociclib (Q60960334) (← links)
• Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia (Q64250050) (← links)
• Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date (Q89538310) (← links)
• Overcoming adaptive therapy resistance in AML by targeting immune response pathways (Q93105342) (← links)
• Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms (Q94686561) (← links)